Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Invested Capital (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Invested Capital for 7 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 89.04% to $1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 89.04% year-over-year, with the annual reading at $1.6 billion for FY2025, 89.04% up from the prior year.
  • Invested Capital for Q4 2025 was $1.6 billion at Kymera Therapeutics, up from $946.3 million in the prior quarter.
  • The five-year high for Invested Capital was $1.6 billion in Q4 2025, with the low at $258.1 million in Q2 2021.
  • Average Invested Capital over 5 years is $620.1 million, with a median of $486.6 million recorded in 2021.
  • The sharpest move saw Invested Capital surged 393.43% in 2021, then dropped 22.88% in 2023.
  • Over 5 years, Invested Capital stood at $459.6 million in 2021, then increased by 6.64% to $490.2 million in 2022, then fell by 19.42% to $395.0 million in 2023, then skyrocketed by 111.56% to $835.6 million in 2024, then soared by 89.04% to $1.6 billion in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $1.6 billion, $946.3 million, and $971.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.